Who is sponsoring NCT05377632?

NCT05377632 is sponsored by Lukas J Hefermehl.

What condition does NCT05377632 study?

NCT05377632 studies Renal Tumor.

Is NCT05377632 still recruiting?

NCT05377632 is currently completed. Last updated 28 November 2025.

Last reviewed 2025-11-28 · How we verify

NCT05377632: PIONEER-OPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparing Two Different Approaches in Robotic-Assisted Renal Surgery

Completed NA Last updated 28 November 2025

What this trial tests

NA trial testing Robotic-assisted laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN) in Renal Tumor in 40 participants. Completed in 15 January 2025.

Timeline

15 May 2022

Primary endpoint
15 December 2024

15 January 2025

Quick facts

Lead sponsor	Lukas J Hefermehl
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	15 May 2022
Primary completion	15 December 2024
Estimated completion	15 January 2025
Sites	1 location across Switzerland

Drugs / interventions tested

Robotic-assisted laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN)

Conditions studied

Renal Tumor — all drugs for Renal Tumor →

Sponsor

Lukas J Hefermehl

Who can join

18 and older, any sex, with Renal Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if the novel TR approach is superior to the standard RP approach. The anticipated study outcome is a time saving of at least 30% from first skin incision to detection of the renal artery compared to the conventional RP approach, and also a better workspace perception by the operating surgeon.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Transabdominal Lumbar Approach (TALA) for Robotic Renal Surgery-A Retrospective Single-Center Comparative Study and Step-by-Step Description of a Novel Approach.
Heining FM, Bieri U, Niemann T, Maletzki P, et al · · 2024 · cited 1× · PMID 38275887 · DOI 10.3390/cancers16020446

Verify or expand the search:

Other recruiting trials for Renal Tumor

Currently open trials in the same condition.

NCT06076538 — PET/MR for Characterization of Renal Masses (RMs) · recruiting
NCT05696444 — Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO) · NA · active not recruiting
NCT03810651 — Pencil Beam Scanning in Patients With Renal Tumors · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05377632 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lukas J Hefermehl
Last refreshed: 28 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05377632.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing